Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27662244 | 0.91 | GPR119 (0.53) | GPR119CYP3A4CYP2C9CCNA2CDK2 | |
| SCHEMBL389064 | 0.89 | GPR119 (0.68) | GPR119CYP2C9 | |
| SCHEMBL390975 | 0.89 | CYP3A4 (0.57) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL4722991 | 0.84 | GPR119 (0.54) | GPR119S1PR1CYP2C9CCNA2CDK2 | |
| SCHEMBL4723218 | 0.84 | GPR119 (0.46) | GPR119CYP3A4CYP2C9CCNA2CDK2 | |
| SCHEMBL27734780 | 0.84 | GPR119 (0.45) | GPR119S1PR1CYP3A4CYP2C9CCNA2 | |
| SCHEMBL28778838 | 0.83 | S1PR1 (0.37) | GPR119S1PR1 | |
| SCHEMBL27755095 | 0.81 | GPR119 (0.37) | GPR119S1PR1CYP3A4CYP2C9 | |
| SCHEMBL27755236 | 0.81 | GPR119 (0.47) | GPR119CYP3A4CYP2C9CCNA2CDK2 | |
| SCHEMBL388776 | 0.80 | GPR119 (0.59) | GPR119CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101332303-A | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level | ARENA PHARM INC (US) | 2008-12-31 | — | — | CN | disclosed |